Chemomab Therapeutics Ltd
CMMB1.020USD
-0.005-0.49%
Fechamento 08/04, 16:00（ET）Cotações atrasadas em 15 min
19.24MValor de mercado
PerdaP/L TTM
Mais detalhes de Chemomab Therapeutics Ltd Empresa
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Informações da empresa
Código da empresaCMMB
Nome da EmpresaChemomab Therapeutics Ltd
Data de listagemAug 14, 2012
CEODr. Adi Mor, Ph.D.
Número de funcionários16
Tipo de títulosDepository Receipt
Fim do ano fiscalAug 14
EndereçoKiryat Atidim, Building 7
CidadeTEL AVIV-YAFO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísIsrael
Código postal6158002
Telefone972773310156
Sitehttps://www.chemomab.com/
Código da empresaCMMB
Data de listagemAug 14, 2012
CEODr. Adi Mor, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
2.56K
-82.97%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.20K
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Investor Relations
Investor Relations
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Jack Lawler
Mr. Jack Lawler
Chief Development Officer
Chief Development Officer
--
--
Dr. David M. Weiner, M.D.
Dr. David M. Weiner, M.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
2.56K
-82.97%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.20K
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Investor Relations
Investor Relations
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 19 de jul
Atualizado em: sáb, 19 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Otto (Erik)
6.03%
Apeiron Investment Group Ltd
5.91%
Rivendell Investments 2017-9 LLC
5.78%
Sphera Funds Management Ltd.
4.70%
Yelin Lapidot Provident Funds Management Ltd
3.02%
Other
74.57%
Investidores
Investidores
Proporção
Otto (Erik)
6.03%
Apeiron Investment Group Ltd
5.91%
Rivendell Investments 2017-9 LLC
5.78%
Sphera Funds Management Ltd.
4.70%
Yelin Lapidot Provident Funds Management Ltd
3.02%
Other
74.57%
Tipos de investidores
Investidores
Proporção
Individual Investor
9.48%
Hedge Fund
5.93%
Family Office
5.91%
Corporation
5.78%
Investment Advisor
3.31%
Research Firm
0.83%
Private Equity
0.69%
Investment Advisor/Hedge Fund
0.20%
Venture Capital
0.07%
Other
67.80%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
36
5.04M
26.29%
-1.09M
2025Q1
38
6.66M
34.89%
+231.83K
2024Q4
41
7.89M
41.83%
+519.06K
2024Q3
37
7.12M
38.75%
+430.17K
2024Q2
36
5.24M
33.24%
-261.90K
2024Q1
39
5.24M
33.39%
-405.62K
2023Q4
41
5.39M
34.50%
+2.72K
2023Q3
43
5.63M
49.23%
-777.20K
2023Q2
42
5.63M
49.23%
-912.41K
2023Q1
44
6.00M
54.09%
-854.86K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Otto (Erik)
1.16M
6.03%
+1.16M
--
Nov 21, 2024
Apeiron Investment Group Ltd
1.13M
5.91%
+404.86K
+55.68%
Dec 31, 2024
Rivendell Investments 2017-9 LLC
1.11M
5.78%
--
--
Dec 31, 2024
Sphera Funds Management Ltd.
900.43K
4.7%
-314.15K
-25.86%
Mar 31, 2025
Yelin Lapidot Provident Funds Management Ltd
578.29K
3.02%
-165.84K
-22.29%
Mar 31, 2025
Mor George (Adi)
317.07K
1.65%
--
--
Dec 31, 2024
Ikarian Capital LLC
213.05K
1.11%
--
--
Mar 31, 2025
George (Kobi)
200.24K
1.04%
-50.91K
-20.27%
Dec 31, 2024
Cohen (Neil Harris)
141.22K
0.74%
-10.00K
-6.61%
Dec 31, 2024
OrbiMed Advisors, LLC
131.27K
0.69%
-1.61M
-92.46%
Jun 23, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Mar 16, 2021
Merger
16<1
Mar 16, 2021
Merger
16<1
Mar 16, 2021
Merger
16<1
Mar 16, 2021
Merger
16<1
Data
Tipo
Proporção
Mar 16, 2021
Merger
16<1
Mar 16, 2021
Merger
16<1
Mar 16, 2021
Merger
16<1
Mar 16, 2021
Merger
16<1
